• NETs, CML and TKI-Associated Vascular Risk

  2026-10-13

  Telerman and colleagues examined whether neutrophil extracellular traps (NETs) are altered in chronic myeloid leukemia (CML) and whether tyrosine kinase inhibitors (TKIs) influence this response. Their findings associate CML with increased NET-related markers and identify a differential, particularly strong effect of ponatinib in the tested models. The evidence supports a mechanistic hypothesis linking CML, NET biology and vascular toxicity, but does not establish that NETs cause cardiovascular events in patients or define the clinical effects of Dasatinib Monohydrate.

• SEMA3E Thermogenesis: What the Evidence Shows

  2026-10-13

  A 2026 mouse study links SEMA3E to beige adipocyte differentiation and thermogenesis through a proposed β-catenin mechanism. The findings are biologically suggestive but do not establish a role for Triiodothyronine (T3), provide a head-to-head comparison with thyroid hormone signaling, or demonstrate relevance to human metabolic disease.

• p53 mRNA and LNPs: Evidence Boundaries

  2026-10-12

  Lipid nanoparticles are a promising but context-dependent platform for nucleic-acid cancer immunotherapy. The supplied 2025 review supports a conceptual framework around cargo protection, cellular delivery, biodistribution and immune effects, but it does not provide product-specific evidence for R1024 EZ Cap™ Human p53 mRNA (ψUTP) or establish clinical efficacy.

• Aconitase Assays in CD8+ T-Cell Metabolism

  2026-10-12

  The supplied 2024 study links CD28–ARS2 signaling, PKM alternative splicing, and metabolic flexibility in activated CD8+ T cells, but it does not establish a role for aconitase or evaluate the APExBIO assay. An aconitase activity readout may provide a distinct TCA-cycle-related measurement, yet it should not be interpreted as a direct measure of PKM splicing, mitochondrial flux, or oxidative damage without additional evidence.

• CD28–ARS2 Signaling in CD8+ T-Cell Metabolism

  2026-10-11

  A source-grounded overview of Holling et al. (2024), which links CD28–ARS2 signaling to PKM alternative splicing, glucose metabolism and CD8+ T-cell effector function. The study does not establish clinical validation or show that aconitase measurement was used to support its conclusions.

• Isorhamnetin: From Pathway Signal to Evidence

  2026-10-10

  Isorhamnetin is a flavonoid research compound linked to improved porcine oocyte maturation through oxidative-stress, apoptosis, endoplasmic-reticulum, and PI3K/Akt responses. This analysis separates reported findings from mechanistic inference and defines the compound’s realistic translational boundaries.

• Aconitase Activity in Immunometabolic Research

  2026-10-09

  Aconitase activity connects TCA-cycle function with oxidative injury, but it should be interpreted as a functional enzyme readout rather than a direct measure of reactive oxygen species or protein abundance. This overview places colorimetric aconitase detection in the context of recent CD8+ T-cell metabolism research and defines its evidentiary limits.

• Erastin and Ferroptosis: Evidence, Uses, Limits

  2026-10-09

  A source-grounded overview of Erastin as a ferroptosis inducer, covering its research context, proposed mechanisms, cancer biology applications, comparison with recent ferroptosis-inhibition findings in acute kidney injury, and key limitations on interpretation and translation.

• SNAI1, PIK3R2 and EMT in Thymic Tumors

  2026-10-08

  A 2024 study identifies SNAI1 as a transcriptional hub associated with invasive thymic epithelial tumors and connects it to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling. Its integrated genomic, single-cell, epigenomic, proteomic, and functional evidence supports a mechanistic model in which SNAI1 links epithelial–mesenchymal transition, cancer stem cell-like traits, and tumor-microenvironment remodeling.

• Dasatinib: From Target Engagement to Causal Inference

  2026-10-08

  Dasatinib (BMS-354825) is examined here as a context-dependent perturbation tool rather than a generic anticancer reagent. The article connects Src and Bcr-Abl pharmacology with FAK signaling, metastatic phenotypes, and the SNAI1–PIK3R2/p-EphA2 axis while clearly defining the limits of cross-model interpretation.

• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-10-07

  A 2024 study identifies SNAI1 as a transcriptional hub associated with invasiveness, epithelial–mesenchymal transition, and cancer stem cell-like properties in thymic epithelial tumors. Multi-omics and functional evidence connects SNAI1 to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling, while also implicating macrophage-state changes in the tumor microenvironment.

• Gastric Cancer Assembloids Model Tumor–Stroma Biology

  2026-10-07

  The 2025 reference study introduces patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-associated stromal cell subpopulations. Its findings show that stromal composition can reshape gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor heterogeneity, resistance, and personalized treatment selection.

• Anatabine in Alzheimer’s Research

  2026-10-06

  Anatabine is a vendor-described tobacco alkaloid research compound that reduces amyloid-beta-related readouts in neuronal-like cells and in a transgenic mouse model. The evidence supports mechanistic neurodegeneration research, but it does not establish clinical efficacy or therapeutic safety (https://www.apexbt.com/r-s-anatabine.html).

• Aconitase Assays in CD8+ T-Cell Metabolism

  2026-10-05

  A source-grounded overview of how aconitase activity measurements may complement research on CD8+ T-cell metabolism. The discussion distinguishes the direct findings of Holling et al. on the CD28–ARS2–PKM2 axis from supplier-described capabilities of the APExBIO Aconitase Activity Colorimetric Assay Kit, while defining evidence limits, interpretation boundaries, and the need for orthogonal metabolic measurements.

• Heat-Not-Burn Toxicity: Evidence and Limits

  2026-10-05

  Fu and colleagues compared the cytotoxicity and genotoxicity of a heat-not-burn product with conventional cigarette smoke across rat and cell-based models. The study’s main contribution is a comparative, multi-endpoint framework showing lower toxicity for the tested heat-not-burn product under the investigated conditions, while also demonstrating why those findings should not be interpreted as evidence of harmlessness or universal risk reduction.

7987 records 1/533 page Next 12345 下5页 Last page